NI-1801 Follow-Up Reports Durable Survival Benefit at 24 Months
Updated Phase 1/1b data on NI-1801 in platinum-resistant ovarian cancer were presented in an oral presentation.
Updated Phase 1/1b data on NI-1801 in platinum-resistant ovarian cancer were presented in an oral presentation.